Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
Eli Lilly (Lilly)
Company facts
- Status
- NYSE LLY
- Headquarters
- INDIANAPOLIS, IN
- Industry
- Pharmaceutical Preparations SIC 2834
- Fiscal year end
- 1231
- Links
- Filings · SEC · Quote · Yahoo
- Source
- SEC
Financial summary (from filings)
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | 34,124 | 45,043 | 65,179 |
| Operating income | — | — | — |
| Net income | 5,240 | 10,590 | 20,640 |
| Total assets | 64,006 | 78,715 | 112,476 |
| Total liabilities | — | — | — |
| Total equity | 10,772 | 14,272 | 26,535 |
Unit: USD million · Consolidated statements · Source SEC 10-K/20-F
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.
Readouts that mention this company
National R&D projects (NTIS)
9
item
2,330,000,000
Cumulative government R&D funding (KRW)
Largest projects
- 개인 맞춤형 화장품 제품 생산을 위한 유연제조 공정시스템 개발 및 실증 2022 · 산업통상자원부
- 도심형 스마트 화장품 스토어 구현을 위한 맞춤형 제조 라인 개발 2020 · 중소벤처기업부
- 머신비전 기반 로봇팔 시스템 및 이동식 원료 카트리지 개발을 통한 맞춤형 화장품 유연 생산 시스템 구축 2026 · 중소벤처기업부
Korean patent filings (KIPRIS)
국내 출원인 표기 없음
Papers with affiliated authors (OpenAlex)
1,209
item
Papers by year
| 2022 |
|---|
| 1,209 |
Companies in the same readouts
- Dong-A ST
- Chugai Pharmaceutical
- Hangzhou Zhongmei Huadong
- Jiangsu Hengrui
- Eccogene
- Novo Nordisk
- Hanmi Pharmaceutical
- LG H&H
Last updated 2026-09-21